A phenotypic screening assay for modulators of huntingtin-induced transcriptional dysregulation

Journal of Biomolecular Screening

Volumn 18, Issue 9, 2013, Pages 984-996

  Lazzeroni, Giulia ^a   Benicchi, Tiziana ^a   Heitz, Freddy ^a,d   Magnoni, Letizia ^b   Diamanti, Daniela ^b   Rossini, Lara ^b   Massai, Luisa ^b   Federico, Cesare ^b   Fecke, Wolfgang ^c,e   Caricasole, Andrea ^b   La Rosa, Salvatore ^b   Porcari, Valentina ^a  

^a Siena Biotech Spa   (Italy)

^b UCB Celltech ^*  (Italy)

^c UCB PHARMA   (Belgium)

^d GENKYOTEX SA   (Switzerland)

^e HansaBioMed OU   (Estonia)

Author keywords

cell based assays; gene expression; phenotypic drug discovery; reporter gene assays

Indexed keywords

4 (1 AMINOETHYL) N (4 PYRIDYL)CYCLOHEXANECARBOXAMIDE; ADENOSINE TRIPHOSPHATE; CYCLIC AMP RESPONSIVE ELEMENT BINDING PROTEIN BINDING PROTEIN; GLUTAMINE; HUNTINGTIN; POLYGLUTAMINE;

AMINO ACID SEQUENCE; ARTICLE; ASSAY; CAG REPEAT; CELL PROLIFERATION; CELL VIABILITY; CLONE; CONCENTRATION RESPONSE; CONTROLLED STUDY; GENETIC TRANSCRIPTION; HIGH THROUGHPUT SCREENING; HUMAN; HUMAN CELL; HUNTINGTON CHOREA; PATHOGENESIS; PHENOTYPIC ASSAY; PRIORITY JOURNAL; REPORTER GENE; REPRODUCIBILITY; TRANSCRIPTION REGULATION; TRANSIENT TRANSFECTION;

CELL-BASED ASSAYS; GENE EXPRESSION; PHENOTYPIC DRUG DISCOVERY; REPORTER GENE ASSAYS;

AMIDES; BIOLOGICAL ASSAY; CELL LINE, TUMOR; CREB-BINDING PROTEIN; GENE EXPRESSION REGULATION; GENES, REPORTER; HUMANS; HUNTINGTON DISEASE; NERVE TISSUE PROTEINS; NEURONS; NEUROPROTECTIVE AGENTS; PEPTIDES; PROTEIN BINDING; PYRIDINES; RESPONSE ELEMENTS; RHO-ASSOCIATED KINASES; SIGNAL TRANSDUCTION; SMALL MOLECULE LIBRARIES; TRANSCRIPTION, GENETIC;

EID: 84884606902     PISSN: 10870571     EISSN: 1552454X     Source Type: Journal    
DOI: 10.1177/1087057113484802     Document Type: Article

References (35)

1. Stack E. C., Ferrante R. J.. Huntington's Disease: Progress and Potential in the Field. Expert Opin. Investig. Drugs. 2007 ; 16: 1933-1953 (Pubitemid 351403725)
2. Andrew S. E., Goldberg Y. P., Kremer B., Telenius H., Theilmann J., Adam S., Starr E., Squitieri F., Lin B., Kalchman M. A., et al. The Relationship between Trinucleotide (CAG) Repeat Length and Clinical Features of Huntington's Disease. Nat. Genet. 1993 ; 4: 398-403 (Pubitemid 23231490)
3. Arrasate M., Finkbeiner S.. Protein Aggregates in Huntington's Disease. Exp. Neurol. 2012 ; 238: 1-11
4. Van Raamsdonk J. M., Pearson J., Murphy Z., Hayden M. R., Leavitt B. R.. Wild-Type Huntingtin Ameliorates Striatal Neuronal Atrophy but Does Not Prevent Other Abnormalities in the YAC128 Mouse Model of Huntington Disease. BMC Neurosci. 2006 ; 7: 80
5. Ross C. A., Thompson L. M.. Transcription Meets Metabolism in Neurodegeneration. Nat Med. 2006 ; 12: 1239-1241 (Pubitemid 44706921)
6. Kaltenbach L. S., Romero E., Becklin R. R.. Huntingtin Interacting Proteins Are Genetic Modifiers of Neurodegeneration. PLoS Genet. 2007 ; 3: e82
7. Luthi-Carter R., Strand A., Peters N. L., Solano S. M., Hollingsworth Z. R., Menon A. S., Frey A. S., Spektor B. S., Penney E. B., Schilling G., et al. Decreased expression of striatal signaling genes in a mouse model of Huntington's disease. Hum. Mol. Genet. 2000 ; 9: 1259-1271 (Pubitemid 30312475)
8. Yamanaka T., Miyazaki H., Oyama F., Kurosawa M., Washizu C., Doi H., Nukina N.. Mutant Huntingtin Reduces HSP70 Expression through the Sequestration of NF-Y Transcription Factor. EMBO J. 2008 ; 27: 827-839 (Pubitemid 351417169)
9. Bae B. I., Xu H., Igarashi S., Fujimuro M., Agrawal N., Taya Y., Hayward S. D., Moran T. H., Montell C., Ross C. A., et al. p53 Mediates Cellular Dysfunction and Behavioral Abnormalities in Huntington's Disease. Neuron. 2005 ; 47: 29-41 (Pubitemid 40922848)
10. Dunah A. W., Jeong H., Griffin A., Kim Y. M., Standaert D. G., Hersch S. M., Mouradian M. M., Young A. B., Tanese N., Krainc D.. Sp1 and TAFII130 Transcriptional Activity Disrupted in Early Huntington's Disease. Science. 2002 ; 296: 2238-2243 (Pubitemid 34680312)
11. Nucifora F. C., Sasaki M., Peters M. F., Huang H., Cooper J. K., Yamada M., Takahashi H., Tsuji S., Troncoso J., Dawson V. L., et al. Interference by Huntingtin and Atrophin-1 with CBP-Mediated Transcription Leading to Cellular Toxicity. Science. 2001 ; 291: 2423-2428 (Pubitemid 32231807)
12. Buckley N. J., Johnson R., Zuccato C., Bithell A., Cattaneo E.. The Role of REST in Transcriptional and Epigenetic Dysregulation in Huntington's Disease. Neurobiol. Dis. 2010 ; 39: 28-39
13. Cui L., Jeong H., Borovecki F., Parkhurst C. N., Tanese N., Krainc D.. Transcriptional Repression of PGC-1alpha by Mutant Huntingtin Leads to Mitochondrial Dysfunction and Neurodegeneration. Cell. 2006 ; 6: 59-69 (Pubitemid 44466642)
14. Pallos J., Bodai L., Lukacsovich T., Purcell J. M., Steffan J. S., Thompson L. M., Marsh J. L.. Inhibition of Specific HDACs and Sirtuins Suppresses Pathogenesis in a Drosophila Model of Huntington's Disease. Hum. Mol. Genet. 2008 ; 17: 3767-3775
15. Jiang M., Wang J., Fu J., Du L., Jeong H., West T., Xiang L., Peng Q., Hou Z., Cai H, et al. Neuroprotective Role of Sirt1 in Mammalian Models of Huntington's Disease through Activation of Multiple Sirt1 Targets. Nat. Med. 2012 ; 18: 153-158
16. Wyttenbach A., Swartz J., Kita H., Thykjaer T., Carmichael J., Bradley J., Brown R., Maxwell M., Schapira A., Orntoft T. F., et al. Polyglutamine Expansions Cause Decreased CRE-Mediated Transcription and Early Gene Expression Changes Prior to Cell Death in an Inducible Cell Model of Huntington's Disease. Hum. Mol. Genet. 2001 ; 10: 1829-1845 (Pubitemid 32899099)
17. Sugars K. L., Brown R., Cook L. J., Swartz J., Rubinsztein D. C.. Decreased cAMP Response Element-Mediated Transcription: An Early Event in Exon 1 and Full-Length Cell Models of Huntington's Disease That Contributes to Polyglutamine Pathogenesis. J. Biol. Chem. 2004 ; 279: 4988-4999 (Pubitemid 38199095)
18. Sakamoto K., Karelina K., Obrietan K.. CREB: A Multifaceted Regulator of Neuronal Plasticity and Protection. J. Neurochem. 2011 ; 116: 1-9
19. Jiang H., Poirier M. A., Liang Y., Pei Z., Weiskittel C. E., Smith W. W., DeFranco D. B., Ross C. A.. Depletion of CBP Is Directly Linked with Cellular Toxicity Caused by Mutant Huntingtin. Neurobiol. Dis. 2006 ; 23: 543-551 (Pubitemid 44234090)
20. Cong S. Y., Pepers B. A., Evert B. O., Rubinsztein D. C., Roos R. A., van Ommen G. J., Dorsman J. C.. Mutant Huntingtin Represses CBP, but Not p300, by Binding and Protein Degradation. Mol. Cell Neurosci. 2005 ; 30: 12-23 (Pubitemid 41133336)
21. Fecke W., Gianfriddo M., Gaviraghi G., Terstappen G. C., Heitz F.. Small Molecule Drug Discovery for Huntington's Disease. Drug Discov. Today. 2009 ; 14: 453-464
22. Varma H.. Drug Screening for Huntington's Disease and Other Neurodegenerative Disorders. Curr. Mol. Pharmacol. 2010 ; 3: 164-173
23. Baldo B., Weiss A., Parker C. N., Bibel M., Paganetti P., Kaupmann K.. A Screen for Enhancers of Clearance Identifies Huntingtin as a Heat Shock Protein 90 (Hsp90) Client Protein. J. Biol. Chem. 2012 ; 287: 1406-1414
24. Coufal M., Maxwell M. M., Russel D. E.. Discovery of a Novel Small-Molecule Targeting Selective Clearance of Mutant Huntingtin Fragments. J. Biomol. Screen. 2007 ; 12: 351-360 (Pubitemid 46514677)
25. Pollitt S. K., Pallos J., Shao J.. A Rapid Cellular FRET Assay of Polyglutamine Aggregation Identifies a Novel Inhibitor. Neuron. 2003 ; 40: 685-694 (Pubitemid 37431030)
26. Aiken C. T., Tobin A. J., Schweitzer E. S.. A Cell-Based Screen for Drugs to Treat Huntington's Disease. Neurobiol. Dis. 2004 ; 16: 546-555 (Pubitemid 38942987)
27. Wang W., Duan W., Igarashi S., Morita H., Nakamura M., Ross C. A.. Compounds Blocking Mutant Huntingtin Toxicity Identified Using a Huntington's Disease Neuronal Cell Model. Neurobiol. Dis. 2005 ; 20: 500-508 (Pubitemid 41476276)
28. Varma H., Cheng R., Voisine C., Hart A. C., Stockwell B. R.. Selective Inhibitors of Death in Mutant Huntingtin Cells. Nat. Chem. Biol. 2007 ; 3: 99-100 (Pubitemid 46134995)
29. Giralt A., Puigdellívol M., Carretón O., Paoletti P., Valero J., Parra-Damas A., Saura C. A., Alberch J., Ginés S.. Long-Term Memory Deficits in Huntington's Disease Are Associated with Reduced CBP Histone Acetylase Activity. Hum. Mol. Genet. 2012 ; 15: 1203-16
30. SittampalamG. S.Gal-EddN.ArkinM.AuldD.AustinC.BejcekB.GlicksmanM. IngleseJ.LemmonV.LiZ.; et al., Eds. Assay Guidance Manual;Eli Lilly & Company and the National Center for Advancing Translational Sciences: Bethesda, MD, 2004. http://www.ncbi.nlm.nih.gov/books/NBK53196/
31. Zhang J. H., Chung T. D., Oldenburg K. R.. A Simple Statistical Parameter for Use in Evaluation and Validation of High Throughput Screening Assays. J. Biomol. Screen. 1999 ; 4: 67-73 (Pubitemid 29278954)
32. Li M., Huang Y., Ma A. A., Lin E., Diamond M. I.. Y-27632 Improves Rotarod Performance and Reduces Huntingtin Levels in R6/2 Mice. Neurobiol. Dis. 2009 ; 36: 413-420
33. Ishizaki T., Uehata M., Tamechika I., Keel J., Nonomura K., Maekawa M., Narumiya S.. Pharmacological Properties of Y-27632, a Specific Inhibitor of Rho-Associated Kinases. Mol. Pharmacol. 2000 ; 57: 976-983 (Pubitemid 30253382)
34. Linseman D. A., Loucks F. A.. Diverse Roles of Rho Family GTPases in Neuronal Development, Survival, and Death. Frontiers Biosci. 2008 ; 13: 657-676 (Pubitemid 351599775)
35. Shaw G., Morse S., Ararat M., Graham F. L.. Preferential Transformation of Human Neuronal Cells by Human Adenoviruses and the Origin of HEK 293 Cells. FASEB J. 2002 ; 16: 869-871